KRAS mutations have been considered a major challenge in cancer research, remaining difficult to overcome for many years. The introduction of Sotorasib has changed this situation, providing a new treatment option for patients with KRAS mutations, especially those with non-small cell lung cancer (NSCLC).
Sotorasib Recommended Adult Dosage
Non-small cell lung cancer/colorectal cancer: 960 mg orally once daily until disease progression or unacceptable toxicity.
Sotorasib Precautions:
(I) Precautions Before Use:
Patient Screening: Before treatment, patients should be screened based on the presence of KRAS G12C mutations in tumor or plasma samples; if the mutation is not detected in the plasma sample, tumor tissue should be tested.
(II) Precautions During Use:
1. Dosage Time and Method: Sotorasib is administered at the same time daily, with or without food.
2. Administration Method: Swallow the tablet whole; do not chew, crush, or break it. 3. Administration for Patients with Dysphagia:
a. Disperse the tablet in 120 ml (4 oz) of non-carbonated room temperature water. Do not crush. Do not use other liquids.
b. Stir until the tablet disperses into small pieces (the tablet will not completely dissolve). Take immediately or within 2 hours. The mixture may appear pale yellow to bright yellow.
c. Swallow the dispersed solution. Do not chew any tablet fragments.
d. Rinse the container with an additional 120 ml (4 oz) of water and drink.
e. If not taken immediately, stir again to ensure the tablet is evenly dispersed.
4. Management of Missed Doses:
If a dose is missed for more than 6 hours, take the next dose as prescribed the following day. Do not take two doses simultaneously to make up for the missed dose.
5. Management of Vomiting:
If vomiting occurs after taking the medication, no additional dose is needed. Take the next dose as prescribed the following day.
Sotorasib Monitoring Recommendations
1. Liver Function Monitoring
Monitoring Indicators
Liver function tests, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin.
Monitoring Frequency
Test before starting sotorasib treatment. For the first 3 months of treatment, test every 3 weeks, then monthly, or as needed clinically. Increase monitoring frequency for patients with elevated transaminases and/or bilirubin.
2. Respiratory System Monitoring
Pay attention for new or worsening lung symptoms, which may indicate interstitial lung disease (ILD) or pneumonia.
Sotorasib Dosage Adjustment
(I) Dose Reduction Due to Adverse Reactions
Initial Dose Reduction: 480 mg sotorasib orally once daily.
Second Dose Reduction: 240 mg sotorasib orally once daily.
(II) Dosage Adjustment for Specific Adverse Reactions
1. Interstitial Lung Disease (ILD)/Pneumonia
Any grade: If ILD/pneumonia is suspected, sotorasib should be discontinued; if ILD/pneumonia is diagnosed, sotorasib should be permanently discontinued.
2. Nausea or vomiting despite appropriate supportive treatment (including antiemetics)
Grade 3-4: Sotorasib should be discontinued until recovery to Grade 1 or below, or baseline level; upon resumption of treatment, the next lower dose level should be used.
3. Diarrhea despite appropriate supportive treatment (including antidiarrheals)
Grade 3-4: Sotorasib should be discontinued until recovery to Grade 1 or below, or baseline level; upon resumption of treatment, the next lower dose level should be used.
4. Other Adverse Reactions
Grade 3-4: Sotorasib should be discontinued until the level returns to Grade 1 or below, or to baseline. When resuming treatment, the next lower dose level should be used.
Sotorasib Dosage Adjustment in Special Populations
(I) Dosage Adjustment for Patients with Renal Impairment
There is currently no relevant data.
(II) Dosage Adjustment for Patients with Hepatic Impairment
Hepatotoxicity Management
1. If Grade 2 AST or ALT elevation occurs with accompanying symptoms, or Grade 3-4 AST or ALT elevation occurs,
the medication should be discontinued until the levels return to Grade 1 or below, or to baseline. When resuming treatment, the next lower dose should be used.
Initial dose reduction: 480 mg, Sotorasib orally once daily.
Second dose reduction: 240 mg, Sotorasib orally once daily.
2. If AST or ALT levels exceed 3 times the upper limit of normal (3×ULN), and total bilirubin levels exceed 2 times the upper limit of normal (2×ULN), and there are no other clear contributing factors,
Sotorasib should be permanently discontinued.
